Antibody response durability following three-dose coronavirus disease 2019 vaccination in people with HIV receiving suppressive antiretroviral therapy


The article “Antibody Response Durability Following Three-Dose Coronavirus Disease 2019 Vaccination in People with HIV Receiving Suppressive Antiretroviral Therapy” investigates the long-term durability of antibody responses in individuals with HIV who are on suppressive antiretroviral therapy (ART) after receiving a three-dose regimen of COVID-19 vaccination.

In this study, the researchers explore how well the immune systems of people living with HIV, who are effectively managing their HIV infection with antiretroviral therapy, respond to and maintain protection from COVID-19 through vaccination.

The findings provide insights into the persistence of antibody responses in this specific population after completing a three-dose COVID-19 vaccination series. This information is crucial for understanding how long the immune protection against COVID-19 may last in individuals with HIV who are on suppressive ART.

The study contributes to our broader understanding of the effectiveness and duration of COVID-19 vaccination in populations with underlying health conditions, such as HIV. Such knowledge is essential for healthcare providers and policymakers to make informed decisions about vaccination strategies for individuals living with HIV, helping to optimize their protection against COVID-19 over time.

Disclaimer: This lay summary was generated by AI and has not been approved by any of the authors yet.

SANTHE is an Africa Health Research Institute (AHRI) flagship programme funded by the Science for Africa Foundation through the DELTAS Africa programme; the Bill & Melinda Gates Foundation; Gilead Sciences Inc.; and the Ragon Institute of Mass General, MIT, and Harvard.